Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
1. Novo Nordisk partners with Septerna for oral medicines in obesity and diabetes. 2. Collaboration includes $2.2 billion incentives across multiple development programs. 3. Novo Nordisk assumes full responsibility for R&D and commercialization efforts. 4. Recent SELECT trial highlights Wegovy's effectiveness in reducing CVD risks. 5. NVO's stock shows a slight increase following the announcement.